Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
26 /100
MEDIUM RISK
Score updated Oct 13, 2026

BDTX — Black Diamond Therapeutics, Inc. Dilution Risk Tracker

Track BDTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BDTX — Get alerts when the score changes →

As of October 13, 2026, Black Diamond Therapeutics, Inc. (BDTX) has a DilutionWatch DilutionScore of 26/100, rated MEDIUM dilution risk. Black Diamond Therapeutics, Inc. has a market capitalization of $101.69M, 57.45M shares outstanding, 106 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰Cash Runway—
📊 Float Risk
5
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for BDTX.
🔔 Track BDTX — Get forecast alerts →

Market Data

Market Cap$101.69M
Shares Outstanding57.45M
Float52.47M
Cash$19.19M
Debt$17.88M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore26/100DilutionWatch score record
Shares Outstanding57.45MVerified float table or market cache
Public Float52.47MVerified float table or market cache
Market Cap$101.69MMarket data cache
Cash RunwayNot applicable / unavailableDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 1.

Recent SEC source mix: XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 0.1% shares (2026Q1 vs prior)
106 institutional holders · 40.54M shares
#1 T. Rowe Price Investment Management, Inc. 10.56M shares
#2 NEA Management Company, LLC 4.45M shares
#3 ACADIAN ASSET MANAGEMENT LLC 2.35M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.78M
Days to Cover7.3
% of Float9.1%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2022-03-17
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual BDTX Dilution Snapshot

Black Diamond Therapeutics, Inc. (BDTX) has a DilutionScore of 26/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

BDTX's DilutionScore is currently 26/100 (Medium risk), with 2 score changes tracked over 89 days. The score deteriorated from 27/100 (Medium risk).

Period Score Risk Level Duration
Sep 30 – Oct 13, 202626/100MEDIUM14 days
Aug 14 – Sep 29, 202627/100MEDIUM46 days
Jul 16 – Aug 13, 202626/100MEDIUM29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

BDTX shares outstanding have increased 0.6% from 56.97M (Mar 2026) to 57.30M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 30, 202657.30M52.47M▲ 13.42%
May 20, 202657.30M46.26M▲ 0.03%
Apr 09, 202657.29M46.25M▼ 0.01%
Mar 23, 202656.97M46.25M▼ 0.01%
Mar 22, 202656.97M46.26M▲ 0.13%
Mar 19, 202656.97M46.20M▲ 0.55%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track BDTX Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment BDTX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking BDTX — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for BDTX
BDTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.